Genetics of Parkinson's disease: LRRK2 on the rise

Brain

Volumn 128, Issue 12, 2005, Pages 2760-2762

  Brice, Alexis ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; LEUCINE RICH REPEAT KINASE 2; UNCLASSIFIED DRUG;

DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HEREDITY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; NERVE CELL DEGENERATION; NOTE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 28544441389     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awh676     Document Type: Note

References (27)

1. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005. Epub ahead of print.
2. Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRSK2 gene in familial and sporadic Parkinson's disease. Brain 2005. In press.
3. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, et al. G2019s dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord 2005. Epub ahead of print.
4. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9.
5. Corti O, Hampe C, Darios F, Ibanez P, Ruberg M, Brice A. Parkinson's disease: from causes to mechanisms. [Review]. C R Biol 2005; 328: 131-42.
6. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365: 412-5.
7. Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, et al. LRRK2 mutations in Parkinson disease. Neurology 2005; 65: 738-40.
8. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51: 296-301.
9. Gasser T. Genetics of Parkinson's disease. [Review]. Curr Opin Neurol 2005; 18: 363-9.
10. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365: 415-6.
11. Hernandez D, Paisan Ruiz C, McInerney-Leo A, Jain S, Meyer-Lindenberg A, Evans EW, et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005; 57: 453-6.
12. Ibanez P, Bonnet AM, Lohmann E, Tison F, Pollak P, Agid Y, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-71.
13. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant Parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76: 672-80.
14. Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 2005; 20: 1077-8.
15. Khan NL, Jain S, Lynch JM et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005. In press.
16. Lesage S, Ibanez P, Lohmann E, et al. The G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005a. In press.
17. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005b; 77: 330-2.
18. Mata IF, Kachergus J, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005. Epub ahead of print.
19. Nicholl DJ, Vaughan JR, Khan NL, Ho SL, Aldous DE, Lincoln S, et al. Two large British kindreds with familial Parkinson's disease: a clinicopathological and genetic study. Brain 2002; 125: 44-57.
20. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, et al. Genetic screening for a single LRRK mutation n in familial Parkinson disease. Lancet 2005; 365: 410-2.
21. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
22. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
23. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005; 384: 327-9.
24. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62: 1619-22.
25. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 2005; 65: 741-4.
26. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004a; 44: 601-7.
27. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004b; 74: 11-9.